ProPhase Labs, Inc. Unrealized Gain (Loss) on Investments
ProPhase Labs, Inc. (PRPH) reported Unrealized Gain (Loss) on Investments of $48.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Cash Flow › Operating Activities
us-gaap:UnrealizedGainLossOnInvestments · last filed 2026-08-19
- ProPhase Labs, Inc. unrealized gain (loss) on investments for the quarter ending 2026-06-30 was $48.00K.
- ProPhase Labs, Inc. unrealized gain (loss) on investments for the quarter ending 2026-03-31 was $225.00K.
- ProPhase Labs, Inc. unrealized gain (loss) on investments for fiscal 2017 was -$78.00K.
| Period end | Unrealized Gain (Loss) on Investments 3 month | Unrealized Gain (Loss) on Investments 6 month | Unrealized Gain (Loss) on Investments 12 month |
|---|---|---|---|
| 2026-06-30 | $48.00K 10-Q · filed 2026-08-19 | $273.00K 10-Q · filed 2026-08-19 | |
| 2026-03-31 | $225.00K 10-Q/A · filed 2026-07-09 | ||
| 2017-12-31 | -$78.00K 10-K/A · filed 2018-08-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |